MA28950B1 - Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine - Google Patents

Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine

Info

Publication number
MA28950B1
MA28950B1 MA29858A MA29858A MA28950B1 MA 28950 B1 MA28950 B1 MA 28950B1 MA 29858 A MA29858 A MA 29858A MA 29858 A MA29858 A MA 29858A MA 28950 B1 MA28950 B1 MA 28950B1
Authority
MA
Morocco
Prior art keywords
cyclosporine
treatment
hepatitis
infections
pharmaceutical composition
Prior art date
Application number
MA29858A
Other languages
English (en)
Inventor
Pietro Scalfaro
Jean-Maurice Dumont
Gregoire Vuagniaux
Rolland-Yves Mauvernay
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Publication of MA28950B1 publication Critical patent/MA28950B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA29858A 2004-10-01 2007-04-27 Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine MA28950B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2004003205 2004-10-01

Publications (1)

Publication Number Publication Date
MA28950B1 true MA28950B1 (fr) 2007-10-01

Family

ID=34959441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29858A MA28950B1 (fr) 2004-10-01 2007-04-27 Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine

Country Status (30)

Country Link
US (3) US7439227B2 (fr)
EP (1) EP1793844B1 (fr)
JP (1) JP4892486B2 (fr)
KR (1) KR101191833B1 (fr)
CN (1) CN101056648B (fr)
AT (1) ATE490778T1 (fr)
AU (1) AU2005290984B2 (fr)
BR (1) BRPI0515494A (fr)
CA (1) CA2580448C (fr)
CY (1) CY1114594T1 (fr)
DE (1) DE602005025232D1 (fr)
DK (1) DK1793844T3 (fr)
EA (1) EA012650B1 (fr)
ES (1) ES2357587T3 (fr)
GE (1) GEP20104960B (fr)
HK (1) HK1104236A1 (fr)
HR (1) HRP20110169T1 (fr)
IL (1) IL182362A0 (fr)
MA (1) MA28950B1 (fr)
MX (1) MX2007003387A (fr)
NZ (1) NZ554412A (fr)
PL (1) PL1793844T3 (fr)
PT (1) PT1793844E (fr)
RS (1) RS51614B (fr)
SG (1) SG139750A1 (fr)
SI (1) SI1793844T1 (fr)
TN (1) TNSN07084A1 (fr)
UA (1) UA88484C2 (fr)
WO (1) WO2006038088A1 (fr)
ZA (1) ZA200702610B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
CN1984671A (zh) 2004-07-14 2007-06-20 诺瓦提斯公司 环孢菌素和peg化干扰素的组合用于治疗丙型肝炎病毒(hcv)的用途
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7696167B2 (en) 2004-11-22 2010-04-13 Astellas Pharma Inc. Cyclic peptide compound
US20090214464A1 (en) * 2004-12-23 2009-08-27 Beat Weidmann Compounds for flaviviridae treatment
RU2007128099A (ru) * 2004-12-23 2009-01-27 Новартис АГ (CH) Композиции для лечения гепатита с
BRPI0613142A2 (pt) * 2005-06-17 2010-12-21 Novartis Ag uso de sangliferina em hcv
EP1931696B1 (fr) 2005-09-30 2011-02-16 Scynexis, Inc. Derives d'arylalkyle et d'heteroarylalkyle de cyclosporine a utilises pour traiter et prevenir une infection virale
WO2007041632A2 (fr) 2005-09-30 2007-04-12 Scynexis, Inc. Procedes et compositions pharmaceutiques pour traiter et prevenir une infection par le virus de l'hepatite c
BRPI0617781A2 (pt) 2005-10-26 2011-08-09 Astellas Pharma Inc compostos de peptìdeos cìclicos
JP5167244B2 (ja) 2006-04-11 2013-03-21 ノバルティス アーゲー Ｈｃｖ／ｈｉｖ阻害剤およびそれらの使用
EP2023918B1 (fr) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporines pour le traitement et la prévention de troubles oculaires
MX2009003743A (es) * 2006-10-12 2009-06-18 Novartis Ag Uso de ciclosporinas modificadas.
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
MX2009011512A (es) 2007-05-02 2009-11-12 Astellas Pharma Inc Nuevos compuestos peptidos ciclicos.
WO2009042892A1 (fr) 2007-09-26 2009-04-02 Oregon Health & Science University Undécapeptides cycliques et leurs dérivés comme thérapies pour la sclérose en plaques
WO2009098533A1 (fr) * 2008-02-08 2009-08-13 Debiopharm Sa Cyclosporine non immunosuppressive pour le traitement de la dystrophie musculaire
CA2724523A1 (fr) 2008-06-06 2010-01-07 Scynexis, Inc. Nouveaux peptides macrocycliques
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
KR20110093858A (ko) * 2008-11-06 2011-08-18 데비오 레쉑쉐 빠르마슈띠끄 에스.아 시클로운데카뎁시펩티드 화합물 및 약제로서 상기 화합물의 용도
AU2009334790B2 (en) 2008-12-31 2016-09-08 Scynexis, Inc. Derivatives of cyclosporin A
NZ594755A (en) 2009-01-30 2013-12-20 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
WO2011063076A1 (fr) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
JP2013513595A (ja) 2009-12-09 2013-04-22 サイネクシス，インコーポレーテッド 新規環状ペプチド
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011141891A1 (fr) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Utilisation de composés cycloundécadepsipeptides
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US20130225483A1 (en) * 2010-10-05 2013-08-29 Claudio Avila New Treatments of Hepatitis C Virus Infection
BR112013008510A2 (pt) 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
RU2013129824A (ru) * 2010-11-30 2015-01-10 Новартис Аг Новое лечение инфекции вируса гепатита с
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
BR112013025021A2 (pt) 2011-03-31 2017-03-01 Novartis Ag alisporivir para tratar infecções por vírus de hepatite c.
ES2533213T3 (es) * 2011-04-01 2015-04-08 Novartis Ag Tratamiento para infección con el virus de hepatitis B solo o en combinación con el virus de hepatitis Delta y enfermedades hepáticas asociadas
MA35029B1 (fr) 2011-04-13 2014-04-03 Novartis Ag Traitement de l'infection par le virus de l'hépatite c avec l'alisporivir
KR20140070565A (ko) * 2011-09-27 2014-06-10 노파르티스 아게 C형 간염 바이러스 감염의 치료를 위한 알리스포리비르
EP2583680A3 (fr) 2011-10-21 2013-06-12 Abbvie Inc. Traitement seul (PSI-7977) ou combinatoire dans l'utilisation pour le traitement du VHC
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
MX2014013625A (es) 2012-05-07 2015-02-05 Novartis Ag Modulacion farmacocinetica con alisporivir.
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
WO2014085623A1 (fr) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Nouveaux analogues de [n-me-4-hydroxyleucine]-9-cyclosporine
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2015008223A1 (fr) 2013-07-17 2015-01-22 Novartis Ag Traitement du virus de l'hépatite c avec l'alisporivir et la ribavirine
CN105579046A (zh) 2013-08-26 2016-05-11 英安塔制药有限公司 用于预防或治疗丙型肝炎的环孢菌素类似物
WO2015136455A1 (fr) 2014-03-13 2015-09-17 Novartis Ag Nouveaux traitements d'une infection par le virus de l'hépatite c
WO2016073480A1 (fr) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Analogues de cyclosporine pour prévenir ou traiter une infection par l'hépatite c
CA3022119A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions therapeutiques a base de nucleotides et nucleosides contenant un alcyne et utilisations associees
TWI780152B (zh) 2017-05-12 2022-10-11 日商中外製藥股份有限公司 環狀有機化合物的製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
AU759480B2 (en) * 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20070073761A (ko) 2007-07-10
JP2008514690A (ja) 2008-05-08
SI1793844T1 (sl) 2011-05-31
HK1104236A1 (en) 2008-01-11
UA88484C2 (ru) 2009-10-26
IL182362A0 (en) 2007-07-24
CA2580448C (fr) 2012-09-18
DE602005025232D1 (de) 2011-01-20
CA2580448A1 (fr) 2006-04-13
GEP20104960B (en) 2010-04-26
EP1793844A1 (fr) 2007-06-13
EA200700725A1 (ru) 2007-10-26
BRPI0515494A (pt) 2008-07-29
ES2357587T3 (es) 2011-04-27
AU2005290984A1 (en) 2006-04-13
CN101056648A (zh) 2007-10-17
ZA200702610B (en) 2008-08-27
ATE490778T1 (de) 2010-12-15
CN101056648B (zh) 2012-08-15
NZ554412A (en) 2011-01-28
HRP20110169T1 (hr) 2011-04-30
MX2007003387A (es) 2007-05-23
US20060252675A1 (en) 2006-11-09
EP1793844B1 (fr) 2010-12-08
TNSN07084A1 (en) 2008-06-02
PT1793844E (pt) 2011-03-10
WO2006038088A1 (fr) 2006-04-13
US7772184B2 (en) 2010-08-10
USRE43371E1 (en) 2012-05-08
US20090081164A1 (en) 2009-03-26
SG139750A1 (en) 2008-02-29
RS51614B (en) 2011-08-31
AU2005290984B2 (en) 2010-09-09
PL1793844T3 (pl) 2011-05-31
KR101191833B1 (ko) 2012-10-16
US7439227B2 (en) 2008-10-21
CY1114594T1 (el) 2016-10-05
JP4892486B2 (ja) 2012-03-07
EA012650B1 (ru) 2009-12-30
DK1793844T3 (da) 2011-03-21

Similar Documents

Publication Publication Date Title
MA28950B1 (fr) Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine
DK1131065T3 (da) Diakyldumarater til behandling af autoimmunsygdomme
MA28740B1 (fr) Methodes de traitement d'infections endobronchiques
BRPI0513370A (pt) uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
ATE314092T1 (de) Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
MA29273B1 (fr) Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur
JP2007522237A5 (fr)
BRPI0515588A (pt) uso de antagonistas de tgf-beta para limitar a nefrotoxicidade de agentes imunossupressivos
NO2019032I1 (no) Treosulfan
DZ3141A1 (fr) Inhibiteurs d'aminotransferase acides aminés-dépendante à chaîne ramifiée, et leur utilisation dans le cadre du traitement de la rétinopathie diabétique.
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
HUP0105070A2 (hu) Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet
MA27474A1 (fr) Vaccin
FR2806911B1 (fr) Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires
DE602004011843D1 (de) Die myocardfunktion wiederherstellende peptidsubstanz
CU20070072A7 (es) Uso de [d-meala]3-[etval]4-ciclosporina para el tratamiento de infección por hepatitis c y composición farmacéutica que comprende la [d-meala]3-[etval]4-ciclosporina
CY1109316T1 (el) Συνδυαστικη αγωγη για πολλαπλη σκληρυνση